AZD3965: Phase I started

Cancer Research U.K. began a 2-part, open-label, dose-escalation, U.K. Phase I trial to evaluate 5, 10, 20 and 30 mg oral AZD3965 given once or twice daily in 28-day cycles for up to 6 cycles in about 63 patients. The first part is slated to enroll about 18 patients with advanced solid tumors or lymphoma. About 45 patients with prostate cancer, gastric cancer or diffuse large B cell lymphoma will be enrolled in the second part. ...